-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gene therapy is a new generation of precision therapy following small molecule and macromolecule targeted thera.
It provides new treatment concepts and methods for tumors, rare diseases, chronic diseases and other intractable diseas.
Long-term, curative effe.
Some time ago, the National Development and Reform Commission issued the "14th Five-Year Plan for Bioeconomic Developmen.
This is China's top five-year plan for bio-economy, and it is also the first top-level design in China's bio-economy fie.
The plan clearly points out that it is necessary to focus on the development of new technologies such as gene diagnosis and treatment, stem cell therapy, and immune cell therapy, strengthen the synergy of production, education, research and application, and accelerate the transformation and clinical application of related technology produc.
Industry analysts believe that from the above documents, it is obvious that the country attaches great importance to the field of gene and cell therapy and is determined to devel.
It is understood that gene therapy refers to the introduction of therapeutic genes into human target cells to correct gene defects and play a precise therapeutic ro.
It is divided into two types of in vivo and in vitro treatmen.
At present, the industry usually classifies cell and gene therapy into one category, collectively referred to as Cell & Gene Therapy, or CGT/GCT for sho.
In recent years, China has been accelerating the development of CGT/market, and with strong policy support, China has already become a fertile ground for the development of global CGT, including WuXi AppTec, GenScript, Heyuan Biotechnology, and Zhaoyan New Dru.
and other local companies are rising rapidly, and the number of gene therapy clinical trial programs is growi.
As of February 2021, a total of 658 gene therapy clinical trial programs have been registered worldwide, of which 40 are in China, accounting for
The industry expects that with the acceleration of review and approval in China and the increase in the number of rare disease patients, the scale of clinical research in this field will continue to expa.
It is worth mentioning that in addition to pharmaceutical companies, many other companies in the industry chain are also accelerating their deployment in this fie.
For example, Tofflon previously disclosed the plan to issue A shares to specific objects in 2022, showing that the number of non-public issuance of shares to no more than 35 specific investors does not exceed 188,501,112 shares (no more than 30% of the company's total share capital before this issuanc.
), plans to raise not more than 2 billion yuan, mainly for the enrichment of the front-end product line (DS) of biopharmaceuticals and cell gene therapy, and the innovation and upgrading and expansion of the injection production line (D.
This also means that Tofflon is making a comprehensive layout in the field of cell gene thera.
The company said that it has a comprehensive product distribution in the field of cell gene therapy, with obvious first-mover advantag.
With the advent of CGT industrialization, it is expected to take over biopharmaceuticals and build the company's next growth cur.
In general, as the gene cell therapy market continues to grow, this field will become more and more popul.
Data shows that from 2016 to 2020, the total financing of the global gene therapy industry has increased significantly from $22 billion to $199 milli.
billion, with a compound annual growth rate of nearly 4
With the expansion of the gene therapy M&A market, the integration of gene therapy technology development and R&D resources will continue to be promoted, which will continue to drive the development of the gene therapy indust.
Data shows that in recent years, the global gene therapy industry has begun to develop rapid.
The market size has grown from US$50 million in 2016 to US$075 billion in 2020, with an average annual compound growth rate of nearly 15
will reach nearly $6 billi.
In China, the market has a compound annual growth rate of 12% from 2016 to 2020, and the market size in 2020 is 28 million yu.
Although the Chinese market started late, it is expected to benefit from favorable policies, advances in medical technology, and an increase in the number of patien.
Under the influence of multiple factors, it is expected to surge to 1885 billion yuan in 202 Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
It provides new treatment concepts and methods for tumors, rare diseases, chronic diseases and other intractable diseas.
Long-term, curative effe.
Some time ago, the National Development and Reform Commission issued the "14th Five-Year Plan for Bioeconomic Developmen.
This is China's top five-year plan for bio-economy, and it is also the first top-level design in China's bio-economy fie.
The plan clearly points out that it is necessary to focus on the development of new technologies such as gene diagnosis and treatment, stem cell therapy, and immune cell therapy, strengthen the synergy of production, education, research and application, and accelerate the transformation and clinical application of related technology produc.
Industry analysts believe that from the above documents, it is obvious that the country attaches great importance to the field of gene and cell therapy and is determined to devel.
It is understood that gene therapy refers to the introduction of therapeutic genes into human target cells to correct gene defects and play a precise therapeutic ro.
It is divided into two types of in vivo and in vitro treatmen.
At present, the industry usually classifies cell and gene therapy into one category, collectively referred to as Cell & Gene Therapy, or CGT/GCT for sho.
In recent years, China has been accelerating the development of CGT/market, and with strong policy support, China has already become a fertile ground for the development of global CGT, including WuXi AppTec, GenScript, Heyuan Biotechnology, and Zhaoyan New Dru.
and other local companies are rising rapidly, and the number of gene therapy clinical trial programs is growi.
As of February 2021, a total of 658 gene therapy clinical trial programs have been registered worldwide, of which 40 are in China, accounting for
The industry expects that with the acceleration of review and approval in China and the increase in the number of rare disease patients, the scale of clinical research in this field will continue to expa.
It is worth mentioning that in addition to pharmaceutical companies, many other companies in the industry chain are also accelerating their deployment in this fie.
For example, Tofflon previously disclosed the plan to issue A shares to specific objects in 2022, showing that the number of non-public issuance of shares to no more than 35 specific investors does not exceed 188,501,112 shares (no more than 30% of the company's total share capital before this issuanc.
), plans to raise not more than 2 billion yuan, mainly for the enrichment of the front-end product line (DS) of biopharmaceuticals and cell gene therapy, and the innovation and upgrading and expansion of the injection production line (D.
This also means that Tofflon is making a comprehensive layout in the field of cell gene thera.
The company said that it has a comprehensive product distribution in the field of cell gene therapy, with obvious first-mover advantag.
With the advent of CGT industrialization, it is expected to take over biopharmaceuticals and build the company's next growth cur.
In general, as the gene cell therapy market continues to grow, this field will become more and more popul.
Data shows that from 2016 to 2020, the total financing of the global gene therapy industry has increased significantly from $22 billion to $199 milli.
billion, with a compound annual growth rate of nearly 4
With the expansion of the gene therapy M&A market, the integration of gene therapy technology development and R&D resources will continue to be promoted, which will continue to drive the development of the gene therapy indust.
Data shows that in recent years, the global gene therapy industry has begun to develop rapid.
The market size has grown from US$50 million in 2016 to US$075 billion in 2020, with an average annual compound growth rate of nearly 15
will reach nearly $6 billi.
In China, the market has a compound annual growth rate of 12% from 2016 to 2020, and the market size in 2020 is 28 million yu.
Although the Chinese market started late, it is expected to benefit from favorable policies, advances in medical technology, and an increase in the number of patien.
Under the influence of multiple factors, it is expected to surge to 1885 billion yuan in 202 Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
